Navigation Links
Karmanos Physician-Scientists Examine Racial Disparities in,Patients with Gynecologic Cancer

of Caucasians due to a less aggressive treatment plan. These treatment plans may be prescribed by the physician, chosen by the patient, or due to a lack of treatment options.

Over seven years, Karmanos physician-scientists followed a group of 170 Caucasian and African American ovarian cancer patients through similar treatment plans, consisting of surgery and chemotherapy. The study revealed, out of the 70 percent of patients who had optimal tumor reduction surgery followed by chemotherapy, the Caucasian patients lived 16-20 months longer than the African American patients.

These results were compared to the Charlson co-morbidity index, which predicts the one-year mortality for a patient who may have a range of co-morbid conditions, such as a patient suffering from cancer along with diabetes.

"African Americans were found to have higher co-morbidity scores, meaning they may have additional factors that contribute to their cancer survivability rate," said Dr. Schimp. "Our study revealed that, in part, a patient's outcome is based on her co-morbidity score, not only on the biology of her cancer or aggressiveness of the cancer treatment."

Based in midtown Detroit, the Barbara Ann Karmanos Cancer Institute is committed to a future free of cancer. The Institute is one of 39 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D. is the Institute's president and CEO.

Barbara Ann Karmanos Cancer Institute

CONTACT: Courtne
'"/>




Page: 1 2 3

Related medicine technology :

1. Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
2. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
6. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
7. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
8. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
9. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
10. Data Presented at the American Academy of Neurologys Annual Meeting Provide Update on Utilization and Safety of Tysabri in Patients with Multiple Sclerosis
11. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
Post Your Comments:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... five times more lethal than other strains and has shown ... used to treat MRSA, according to a Henry Ford Hospital ... patients infected with the strain died within 30 days compared ... The average 30-day mortality rate for MRSA bloodstream ...
... receive a kidney transplant rarely develop the serious inflammatory ... a paper being presented at the American Society of ... Diego, CA. The findings indicate that having lupus should ... they need one. Individuals with the autoimmune disease ...
... A Henry Ford Hospital study found that hepatitis B does not ... is a contributing factor. The results contradict a previous ... previous hepatitis B infection. Hepatitis B is an inflammation of the ... presented at the American Association for the Study of Liver Diseases, ...
... ... Ontario health care professionals will hear firsthand from some of the ... in North America at an international conference on the diagnosis and treatment ... in the vitamin D field are presenting information that looks at the ...
... Amgen (Nasdaq: AMGN ) today announced the ... Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, ... kidney disease (CKD) not on dialysis, moderate anemia and ... New England Journal of Medicine and presented ...
... Oct. 30 Today Company C announced it will ... Komen for the Cure®. , On Saturday and Sunday, ... Passion for Pink event, during which 15 percent of all ... and local breast cancer awareness, research and education. A New ...
Cached Medicine News:Health News:Henry Ford Hospital study: A MRSA strain linked to high death rates 2Health News:Kidney transplants generally safe for lupus patients 2Health News:Toronto Conference Targets the Vitamin D Deficiency Crisis 2Health News:Toronto Conference Targets the Vitamin D Deficiency Crisis 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 2Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 4Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 5Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 6Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 7Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 8Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 9Health News:Company C Donates $40,000 To Fight Breast Cancer 2
... The Dimension Vista 1500 ... turbidemetry, nephelometry, IMT (integrated multisensor ... new design will integrate analysis ... chemistries, drugs-of-abuse, therapeutic drugs, immunosuppressive ...
... high performance portable ultrasound design provides ... echocardiography. Echocardiography (ultrasound) imaging requires ... and sensitive Doppler performance. The ... Terason's proprietary Teratech Architecture, delivers a ...
... passes through the GI tract, it transmits data ... the SmartPill Data Receiver, a small, light-weight, battery ... (supported by either a belt or lanyard). The ... measurement data, and elapsed and real time. After ...
... Endoscopic cases it is extremely popular to combine ... Light. This combination affords the surgeon optimal ... an uncomfortable pose. The Dual Light System ... System. As such the light can be ...
Medicine Products: